Argenica Therapeutics (CHIA:AGN) - Stock Price, News & Analysis

AGN Stock Overview

A biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia.

AGN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 34% per year over past 5 years

Does not have meaningful revenue (A$3M)

Shareholders have been diluted in the past year

Does not have a meaningful market cap (A$92M)

Argenica Therapeutics Limited Competitors

Percheron Therapeutics

ASX:PER

AU$94.7m

Recce Pharmaceuticals

ASX:RCE

AU$120.4m

Vitura Health

ASX:VIT

AU$43.8m

ECS Botanics Holdings

ASX:ECS

AU$23.2m

Price History & Performance

Summary of all time highs, changes and price drops for Argenica Therapeutics
Historical stock prices
Current Share Price	AU$0.72
52 Week High	AU$0.95
52 Week Low	AU$0.29
Beta	0.79
11 Month Change	-8.28%
3 Month Change	-12.20%
1 Year Change	97.26%
33 Year Change	71.43%
5 Year Change	n/a
Change since IPO	176.92%

Recent updates

Shareholder Returns

	AGN	AU Pharmaceuticals	AU Market
7D	-5.3%	-6.3%	-0.7%
1Y	97.3%	82.1%	17.1%

Return vs Industry: AGN exceeded the Australian Pharmaceuticals industry which returned 82.1% over the past year.

Return vs Market: AGN exceeded the Australian Market which returned 17.1% over the past year.

Price Volatility

Is AGN's price volatile compared to industry and market?
AGN volatility
AGN Average Weekly Movement	8.4%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

Stable Share Price: AGN has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: AGN's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2019	n/a	Liz Dallimore	argenica.com.au

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.

Argenica Therapeutics Limited Fundamentals Summary

How do Argenica Therapeutics's earnings and revenue compare to its market cap?
AGN fundamental statistics
Market cap	AU$91.54m
Earnings (TTM)	-AU$5.48m
Revenue (TTM)	AU$2.60m

35.2x

P/S Ratio

-16.7x

P/E Ratio

Is AGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGN income statement (TTM)
Revenue	AU$2.60m
Cost of Revenue	AU$0
Gross Profit	AU$2.60m
Other Expenses	AU$8.08m
Earnings	-AU$5.48m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.043
Gross Margin	100.00%
Net Profit Margin	-210.92%
Debt/Equity Ratio	0%

How did AGN perform over the long term?

See historical performance and comparison

AGN Stock Overview

Rewards

Risk Analysis

Argenica Therapeutics Limited Competitors

ASX:PER

AU$94.7m

ASX:RCE

AU$120.4m

ASX:VIT

AU$43.8m

ASX:ECS

AU$23.2m

Price History & Performance

Recent News & Updates

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

New minor risk - Share price stability

Recent updates

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

New minor risk - Share price stability

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

New major risk - Share price stability

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Less than half of directors are independent

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Shareholder Returns

Price Volatility

About the Company

Argenica Therapeutics Limited Fundamentals Summary

35.2x

-16.7x

Earnings & Revenue